Search PBYI
PUMA BIOTECHNOLOGY, INC.
Nasdaq · CIK 1401667
Last close9.51
Daily change-0.33 (-3.35%)
10 Years gain-85.18%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
PBYI · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
50.6Momentum
48.3Acceleration
48.3Confidence
83.0Annual Revenue9
Quarterly Revenue37
Annual CFO14
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.9 / 25
Quality12.1 / 25
Capital Efficiency20.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 5.3264 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Inventory anomaly · MEDIUMInventory growth is materially above revenue growth.
Key Metrics
Revenue Growth TTM-4.22%OK
Revenue CAGR 3Y0.05%OK
Gross Margin77.25%OK
Operating Margin9.59%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC29.97%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y5.39%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $228.37M | $170.21M | $37.30M | $41.80M | $41.73M | 74.53% | 16.33% | 18.27% | 56.57% | 50.65M |
| 2025 FY Dec 31, 2024 | $230.47M | $166.06M | $30.97M | $38.92M | $38.86M | 72.06% | 13.44% | 16.86% | 38.81% | 49.1M |
| 2025 FY Dec 31, 2023 | $235.64M | $172.96M | $32.64M | $27.01M | $26.87M | 73.4% | 13.85% | 11.4% | 60.92% | 47.55M |
| 2024 FY Dec 31, 2022 | $228.03M | $172.94M | $23.72M | -$15.83M | -$15.83M | 75.84% | 10.4% | -6.94% | 51.41% | 44.93M |
| 2023 FY Dec 31, 2021 | $253.16M | $189.45M | $1.29M | $20.65M | $20.65M | 74.84% | 0.51% | 8.16% | 95.56% | 40.64M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $208.23M | sum latest 4 fiscal quarters Revenue | OK | 0001437749-26-026311, 0001437749-25-033633 |
| Revenue Growth TTM | -4.22% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001437749-26-026311, 0001437749-25-033633 |
| Revenue CAGR 3Y | 0.05% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001437749-26-005891 |
| Revenue CAGR 5Y | 0.29% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001437749-26-005891 |
| Gross Profit CAGR 3Y | -0.53% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001437749-26-005891 |
| Operating Income Growth | -7.5% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001437749-26-026311, 0001437749-25-033633 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 77.25% | Gross Profit / Revenue | OK | 0001437749-26-026311, 0001437749-25-033633 |
| Operating Margin | 9.59% | Operating Income / Revenue | OK | 0001437749-26-026311, 0001437749-25-033633 |
| ROIC | 29.97% | NOPAT / Average Invested Capital | OK | 0001437749-26-026311, 0001437749-25-033633 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001437749-26-026311 |
| Current Ratio | 2.91x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $3.96 | Revenue / Diluted Shares | OK | 0001437749-26-026311, 0001437749-25-033633 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |